Human immunodeficiency virus type 1 (HIV-1) targets important cells of our immune system, making infected individuals more ...

So far, the FDA has approved the drug only for people who already have HIV that’s resistant to other treatments. But its ...

Gilead Sciences Inc (NASDAQ: GILD) is strongly positioned to “change the face of HIV” in 2025, according to its chairman and ...

Global leaders must urgently prioritise and work to provide access to new long-acting HIV prevention -- and potentially ...

It’s all the more tragic because HIV drugs can keep people from catching the virus, and prevent those living with the virus from passing it on. If everyone who needed these drugs could access them, ...

UNAIDS urges speed and compassion urging pharmaceutical companies to enable access to new, life-saving medicinesDAVOS/GENEVA, ...

Researchers at the Max Planck Institute of Biophysics and Heidelberg University have observed largely intact HIV-1 capsids as ...

Lenacapavir has the potential to transform HIV care and prevention, but only if access is broadened, according to Jose Abrigo ...

What challenges do regions such as Africa and Latin America face around access to HIV medicines? We have recently seen ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Meanwhile, the recent approval of lenacapavir by the US Federal Drug Administration (FDA) has come as a significant ...